SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as essential decentralized finance infrastructure, bolstered by a recent partnership with the U.S. Department of Commerce to provide macroeconomic data on-chain. The community is actively discussing the project's strong institutional backing, revenue-sharing model through token buybacks, and its growing importance within the Real World Asset (RWA) sector.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The 4CHAN token is trending as a cultural index, with community members branding it the "Bitcoin of memecoins" due to its origins as the birthplace of major internet memes. While some retail traders are debating its volatility and long-term potential, the community is actively encouraging others to accumulate during market dips and hold through structural price fluctuations.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing community attention as traders highlight its recent price resilience and YTD outperformance against Bitcoin, fueling speculation of a major breakout. Conversations are dominated by anticipation for the upcoming 2026 'Layla' network upgrade, with many users debating its potential to reclaim status as a top-tier peer-to-peer electronic cash platform while others remain skeptical of its long-term momentum.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as investors debate the potential for a recovery amid active discussions about its decentralized AI agent infrastructure and recent volatility. The community remains polarized, with some focused on long-term utility and accumulation opportunities while others express frustration over price performance and the ongoing fallout from the ASI merger.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is trending as investors weigh strong earnings and high-growth potential in its immunology and oncology pipelines against ongoing regulatory scrutiny at a third-party manufacturing facility. Community sentiment remains mixed, with bullish long-term investors pointing to strong fundamentals and potential label expansions, while traders express frustration over the stock's volatility and recent supply-chain related delays.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Illumina Inc

Illumina is trending as investors react to the company's long-term strategy for operational efficiency and value creation, even as it navigates significant headwinds from international trade tensions and a ban on its gene sequencers in China. The community remains divided, with some highlighting the stock's potential as a leader in precision medicine and genomics data, while others express caution regarding the company's slowing revenue growth and its high valuation relative to current performance.

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Exelixis is currently navigating market volatility following Merck's announcement that the combination of Welireg and Lenvima outperformed Exelixis's Cabometyx in a key Phase 3 trial for renal cell carcinoma. While investors weigh the potential loss of market share in the second-line treatment setting against the company's established revenue, the community remains divided between those focused on the stock's growth potential and those concerned about increased competitive pressure.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals remains a focal point for investors as the biotech sector evaluates RNA interference leadership, with active community discussion centered on both the company's strong commercial pipeline and the broader competitive landscape of genetic medicine. Market participants are closely watching the companys ongoing clinical developments and potential strategic collaborations as catalysts that could influence its long-term growth trajectory.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy is experiencing significant volatility driven by a major earnings miss and investor caution ahead of potential equity dilution, while the long-term bullish thesis remains centered on its role as the only licensed U.S. producer of HALEU fuel for critical nuclear infrastructure. The community is actively debating the company's valuation versus its strategic necessity, with many traders focused on technical support levels and the potential for a recovery as the sector benefits from sustained federal funding and increasing energy demands from AI data centers.

EQT Corp. is a natural gas production company, which engages in the provision of supply, transmission, and distribution of natural gas. The company was founded in 1888 and is headquartered in Pittsburgh, PA.

EQT Corp

EQT Corp is drawing investor attention as it reports a significant earnings beat and raises production guidance, highlighting strong operational efficiency and cost management. The community is actively debating the company's long-term value proposition as it positions itself to capitalize on growing natural gas demand from AI data centers and evolving infrastructure needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Retail chatter around Creative Medical Technology Holdings picked up on Wednesday after the company said the U.S. Food and Drug Administration (FDA)&nbsp;had granted Fast Track status to its lead experimental treatment, CELZ-201-DDT, for degenerative disc disease (DDD), which is a leading cause of chronic lower back pain and disability.<a href="https://stocktwits.com/symbol/CELZ">Creative Medical’s stock</a> rose 4.70% to $3.23 on Wednesday before slipping 2.8% in after-hours trading.The Fast Track designation is reserved for treatments that have the potential to address serious health conditions with limited existing treatment options.&nbsp;It allows for more frequent contact with the FDA, rolling submissions of the company’s Biologics License Application, and the possibility of priority review, potentially speeding the path to market.CELZ-201-DDT is part of Creative Medical’s AlloStem platform and uses allogeneic perinatal cells, delivered through minimally invasive, ultrasound-guided intramuscular injections.&nbsp;&nbsp;The FDA's decision was based on clinical data that demonstrated the treatment's safety and evidence that the therapy may help patients.&nbsp;CEO Timothy Warbington said the designation was not only a scientific validation, but also a milestone that could accelerate development and address the unmet need for novel, non-addictive therapies for back pain at a time when the U.S. is in the midst of an opioid crisis.DDD affects millions worldwide, with current care often limited to pain management or surgery. Creative Medical is aiming to treat the root causes, which are degeneration and inflammation, rather than just the symptoms.&nbsp;The company stated that the potential market for innovative therapies for spinal disorders could reach over $20 billion by 2030.Within 15 days, Creative Medical will post its expanded access policy for CELZ-201-DDT.On Stocktwits, retail sentiment for Creative Medical was ‘extremely bullish’ amid a 3,600% surge in 24-hour message volume.One user said they were adding to their Creative Medical position on every dip, expecting the stock to move above 4.&nbsp;<stembedurl>https://stocktwits.com/Dickman777/message/624985970</stembedurl>Another user said that if there is little to no new dilution, the shares should be trading at 32 rather than 3.20.<stembedurl>https://stocktwits.com/Peterb3346/message/624989829</stembedurl>Creative Medical’s stock has risen nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Creative Medical Technology Holdings (CELZ) picked up on Wednesday after the company said the U.S. FDA had granted Fast Track status to CELZ-201-DDT. (Photo credit: Getty Images)

Retail Traders Pile Into Creative Medical After FDA Fast Tracks Degenerative Disc Disease Therapy

The company estimates that the potential market for innovative treatments for spinal disorders could exceed $20 billion by 2030.

Equity

New Strong Sell Stocks for July 31st

CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.

CELZ
Creative Medical Technology Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CELZ News

CELZCreative Medical Technology Holdings Inc